Minocycline for retinitis pigmentosa
Treatments studied
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests whether the antibiotic minocycline can slow vision loss from retinitis pigmentosa. If you are between 18 and 60 and have some remaining sight, this study may help find a new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with retinitis pigmentosa, with reduced electrical activity in your retinas and narrowed side vision.
- In at least one eye, a special eye test (30Hz flicker ERG) shows some remaining retinal activity.
- Your vision in both eyes can be corrected to a certain level (measured on a standard eye chart).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called IGT001 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The goal is to see if it is safe and can help slow or improve vision.
This study tests an extract from a type of algae that is rich in a special form of vitamin A. It may help improve vision for people with retinitis pigmentosa caused by certain gene mutations that affect how the eye processes vitamin A.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This trial tests an algae-derived powder taken by mouth to see if it can improve visual function in teenagers with retinitis pigmentosa. Because it’s early-stage, it focuses on safety and early signs of benefit to vision tests.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.